Author of

• 25955

  +

  P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27367

    +

    P3.01-16 - Low Dose Apatinib Combined with EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure (ID 13675)

    12:00 - 13:30  |  Author(s): Junli Song
    • Abstract
    • Slides

    Background
    

    EGFR TKIs have been approved as the first-line therapy for treating advanced non-small-cell lung cancer (NSCLC). However, treatment failures frequently occurred in NSCLC patients with EGFR-sensitizing mutations. Apatinib, a novel small molecule TKI targeted VEGFR2, recommended as third-line treatment for metastatic gastric cancer patients. This retrospective study tried to investigate the efficacy and safety of low dose Apatinib combined with original targeted drugs in treating advanced NSCLC after first-generation EGFR-TKIs treatment failure and trying to explore the underlying mechanisms.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    From March 2016 to November 2016, 11 patients of advanced NSCLC acquired resistance for Erlotinib, gefitinib and Icotinib treated with original targeted drugs plus Apatinib（250 mg, once daily）, and CT scan every 4 weeks. Meanwhile observe drug-related adverse events.

    4c3880bb027f159e801041b1021e88e8 Result
    

    In 11 patients, there were 10 patients available for efficacy and safety evaluation. 2 of 10 patients were progress disease in 12 weeks, 8 of 10 patients were stable disease and still in treatment. The disease control rate (DCR) was 80%. The rate of PFS at 12 weeks was 72.73%. The most frequent treatment-related adverse events were fatigue (20%, 2/10), rash (20%, 2/10), poor appetite (20%, 2/10), respectively. Severe AEs included grade 3 proteinuria (10%, 1/10).

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Low dose Apatinib combined with original targeted drugs is efficacious in treating patients with advanced NSCLC who failed to first-generation EGFR-TKIs treatment, with acceptable toxic effects. The mechanism may be related to Apatinib regulate tumor microenvironment and reverses multidrug resistance.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.